Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14709471 | 0.81 | SMN1; SMN2 (0.36) | L3MBTL1SMN1; SMN2TSHRGLAALDH1A1 | |
| SCHEMBL707800 | 0.80 | PTPN1 (0.40) | L3MBTL1CCR2SMN1; SMN2TSHRGLA | |
| SCHEMBL2521711 | 0.80 | HTR2A (0.38) | SMN1; SMN2TSHRALDH1A1LMNAHTT | |
| SCHEMBL15413756 | 0.79 | LMNA (0.49) | L3MBTL1SMN1; SMN2TSHRGLAALDH1A1 | |
| SCHEMBL1015757 | 0.78 | PYCR1 (0.40) | SMN1; SMN2TSHRGLAALDH1A1CA1 | |
| SCHEMBL25256937 | 0.77 | CA1 (0.39) | L3MBTL1CCR2SMN1; SMN2TSHRGLA | |
| SCHEMBL18498758 | 0.77 | CCR2 (0.41) | L3MBTL1CCR2SMN1; SMN2TSHRGLA | |
| SCHEMBL12179589 | 0.77 | PTGDR2 (0.42) | L3MBTL1CCR2TSHRALDH1A1CA1 | |
| SCHEMBL18498709 | 0.77 | L3MBTL1 (0.39) | L3MBTL1CCR2SMN1; SMN2TSHRGLA | |
| SCHEMBL5673837 | 0.77 | PYCR1 (0.41) | SMN1; SMN2TSHRCA1CA2SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544095-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | PFIZER INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180222862-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2018-08-09 | — | — | US | disclosed |
| EP-3334733-A1 | 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Pfizer Inc (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017025868-A1 | 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PFIZER INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544095-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | TDO2, IDO1, IDO2 | L3MBTL1 3235/4885CCR2 1436/4885SMN1; SMN2 1096/4885 |
| US-20180222862-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | L3MBTL1 3522/4885CCR2 1169/4885SMN1; SMN2 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.